The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma

被引:40
作者
Hamilton, Robert J. [1 ,6 ]
Morilla, Daniel [7 ]
Cabrera, Fernando [4 ]
Leapman, Michael [5 ]
Chen, Ling Y. [2 ]
Bernstein, Melanie [1 ]
Hakimi, A. Ari [1 ]
Reuter, Victor E. [3 ]
Russo, Paul [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, Surg Pathol Diagnost Serv, New York, NY 10065 USA
[4] Suny Downstate Med Ctr, Dept Urol, New York, NY USA
[5] Mt Sinai Med Ctr, Dept Urol, New York, NY 10029 USA
[6] Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada
[7] Tripler Army Med Ctr, Urol Serv, Honolulu, HI 96859 USA
关键词
kidney neoplasms; hydroxymethylglutaryl-CoA reductase inhibitors; nephrectomy; disease progression; chemoprevention; BREAST-CANCER RECURRENCE; PROSTATE-CANCER; RADICAL PROSTATECTOMY; BIOCHEMICAL RECURRENCE; PROSPECTIVE COHORT; RISK; METAANALYSIS; DATABASE; MEN;
D O I
10.1016/j.juro.2013.10.141
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Evidence suggests that statins may influence pathways of renal cell carcinoma proliferation, although to our knowledge no study has examined the influence of statin medications on the progression of renal cell carcinoma in humans. Materials and Methods: We identified 2,608 patients with localized renal cell carcinoma who were treated surgically between 1995 and 2010 at our tertiary referral center. Competing risks Cox proportional hazards models were used to evaluate the relationship between statin use and time to local recurrence or progression (metastases or death from renal cell carcinoma) and overall survival. Statin use was modeled as a time dependent covariate as a sensitivity analysis. Models were adjusted for clinical and demographic features. Results: Of 2,608 patients 699 (27%) were statin users at surgery. Statin users had similar pathological characteristics compared to nonusers. At a median followup of 36 months there were 247 progression events. Statin use was associated with a 33% reduction in the risk of progression after surgery (HR 0.67, 95% CI 0.47-0.96, p = 0.028) and an 11% reduction in overall mortality that was not significant (HR 0.89, 95% CI 0.71-1.13, p = 0.3). Modeling statin use as a time dependent covariate attenuated the risk reduction in progression to 23% (HR 0.77, p = 0.12) and augmented the risk reduction in overall survival (HR 0.71, p = 0.002). Conclusions: In our cohort statin use was associated with a reduced risk of progression and overall mortality, although this effect was sensitive to the method of analysis. If validated in other cohorts, this finding warrants consideration of prospective research on statins in the adjuvant setting.
引用
收藏
页码:914 / 919
页数:6
相关论文
共 27 条
  • [1] Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
    Ahern, Thomas P.
    Pedersen, Lars
    Tarp, Maja
    Cronin-Fenton, Deirdre P.
    Garne, Jens Peter
    Silliman, Rebecca A.
    Sorensen, Henrik Toft
    Lash, Timothy L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (19): : 1461 - 1468
  • [2] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    Baigent, C.
    Blackwell, L.
    Emberson, J.
    Holland, L. E.
    Reith, C.
    Bhala, N.
    Peto, R.
    Barnes, E. H.
    Keech, A.
    Simes, J.
    Collins, R.
    [J]. LANCET, 2010, 376 (9753) : 1670 - 1681
  • [3] Association between Statins and Prostate Tumor Inflammatory Infiltrate in Men Undergoing Radical Prostatectomy
    Banez, Lionel L.
    Klink, Joseph C.
    Jayachandran, Jayakrishnan
    Lark, Amy L.
    Gerber, Leah
    Hamilton, Robert J.
    Masko, Elizabeth M.
    Vollmer, Robin T.
    Freedland, Stephen J.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (03) : 722 - 728
  • [4] Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro
    Bil, Jacek
    Zapala, Lukasz
    Nowis, Dominika
    Jakobisiak, Marek
    Golab, Jakub
    [J]. CANCER LETTERS, 2010, 288 (01) : 57 - 67
  • [5] Statin use and the risk of kidney cancer: a population-based case-control study
    Chiu, Hui-Fen
    Kuo, Chien-Chun
    Kuo, Hsin-Wei
    Lee, I-Ming
    Lee, Chien-Te
    Yang, Chun-Yuh
    [J]. EXPERT OPINION ON DRUG SAFETY, 2012, 11 (04) : 543 - 549
  • [6] Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy -: A multicenter European study
    Cindolo, L
    Patard, JJ
    Chiodini, P
    Schips, L
    Ficarra, V
    Tostain, J
    de La Taille, A
    Altieri, V
    Lobel, B
    Zigeuner, RE
    Artibani, W
    Guillé, F
    Abbou, CC
    Salzano, L
    Gallo, C
    [J]. CANCER, 2005, 104 (07) : 1362 - 1371
  • [7] Statin use and the risk of 10 cancers
    Coogan, Patricia F.
    Rosenberg, Lynn
    Strom, Brian L.
    [J]. EPIDEMIOLOGY, 2007, 18 (02) : 213 - 219
  • [8] Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients
    Friedman, Gary D.
    Flick, E. Dawn
    Udaltsova, Natalia
    Chan, James
    Quesenberry, Charles P., Jr.
    Habel, Laurel A.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (01) : 27 - 36
  • [9] The risk of cancer in users of statins
    Graaf, MR
    Beiderbeck, AB
    Egberts, ACG
    Richel, DJ
    Guchelaar, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2388 - 2394
  • [10] Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy
    Gutt, Ruchika
    Tonlaar, Nathan
    Kunnavakkam, Rangesh
    Karrison, Theodore
    Weichselbaum, Ralph R.
    Liauw, Stanley L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2653 - 2659